{"id":"NCT05067127","sponsor":"Apellis Pharmaceuticals, Inc.","briefTitle":"Phase III Study Assessing the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","officialTitle":"A Phase 3, Randomized, Placebo-Controlled, Double-Blinded, Multicenter Study to Evaluate the Efficacy and Safety of Pegcetacoplan in Patients With C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2021-11-12","primaryCompletion":"2024-06-26","completion":"2025-01-14","firstPosted":"2021-10-05","resultsPosted":"2025-08-06","lastUpdate":"2025-08-06"},"enrollment":124,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"TRIPLE","primaryPurpose":"TREATMENT"},"conditions":["C3G","IC-MPGN","C3 Glomerulopathy","C3 Glomerulonephritis","Complement 3 Glomerulopathy","Complement 3 Glomerulopathy (C3G)","Complement 3 Glomerulonephritis","Dense Deposit Disease","DDD","Membranoproliferative Glomerulonephritis","Membranoproliferative Glomerulonephritis (MPGN)","Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN)"],"interventions":[{"type":"DRUG","name":"Pegcetacoplan","otherNames":[]},{"type":"OTHER","name":"Placebo","otherNames":[]}],"arms":[{"label":"Group 1: Pegcetacoplan administration","type":"EXPERIMENTAL"},{"label":"Group 2: Placebo administration","type":"PLACEBO_COMPARATOR"}],"summary":"This is a Phase 3 study to assess the efficacy and safety of twice-weekly subcutaneous (SC) doses of pegcetacoplan compared to placebo in patients with C3 glomerulopathy (C3G) or immune-complex membranoproliferative glomerulonephritis (IC-MPGN) on the basis of a reduction in proteinuria.","primaryOutcome":{"measure":"Randomized Controlled Period: Change From Baseline in Log-Transformed Urine Protein-to-Creatinine Ratio (uPCR) at Week 26","timeFrame":"Baseline (Day -70 to Day 1) to Week 26","effectByArm":[{"arm":"Randomized Controlled Period: Pegcetacoplan","deltaMin":-1.114,"sd":null},{"arm":"Randomized Controlled Period: Placebo","deltaMin":0.029,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":"<0.0001"}]},"eligibility":{"minAge":"12 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":125,"countries":["United States","Argentina","Australia","Austria","Belgium","Brazil","Canada","Czechia","France","Germany","Israel","Italy","Japan","Netherlands","Poland","South Korea","Spain","Switzerland","United Kingdom"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":6,"n":63},"commonTop":["Headache","Pyrexia","Nasopharyngitis","Vomiting","Diarrhoea"]}}